There’s positive news for those battling Mucopolysaccharidosis (MPS), a rare group of genetic disorders. The Mucopolysaccharidosis Treatment Market is experiencing significant growth, projected to reach a substantial USD 3.37 billion by 2029. This signifies a strong CAGR (Compound Annual Growth Rate) of 5.9%, building on a market value of roughly USD 2.38 billion in 2022. According …